enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$2.41+0.13 (+5.70%)
Close on Nov 13, 2026Market cap $161.51MP/E –Yield 0.00%
enGene Therapeutics total assets
Total assets on the balance sheet at the end of each period.
enGene Therapeutics's total assets was $288.32M at Jul 31, 2026. For fiscal 2025 it was $221.47M, down 28.8% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $221.47M | -28.8% |
| FY2024 | Oct 31, 2024 | $311.17M | +257.8% |
| FY2023 | Oct 31, 2023 | $86.96M | +263.7% |
| FY2022 | Oct 31, 2022 | $23.91M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $288.32M | +17.4% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $307.52M | +15.3% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $337.11M | +17.9% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $221.47M | -28.8% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $245.55M | -8.0% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $266.65M | -2.5% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $285.93M | +206.1% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $311.17M | +257.8% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $266.88M | +1016.2% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $273.53M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $93.42M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $86.96M | – |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | $23.91M | – |
See a number that looks wrong?